Is GKOS a Buy? What to Consider in 2026
Short answer
The bull case for Glaukos Corporation (GKOS) rests on iDose TR ramp: The iDose TR sustained-release glaucoma implant is the single biggest growth driver, contributing around $54 million in Q1 2026 and powering the US glaucoma franchise up roughly 58% year over year. Revenue (TTM) is ~$470M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Whether GKOS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Glaukos Corporation is a San Clemente, California ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease. It pioneered Micro-Invasive Glaucoma Surgery (MIGS) with the iStent family of implants and has expanded into sustained-release drug delivery with iDose TR (a glaucoma implant) and corneal therapies including Photrexa and the newer Epioxa cross-linking treatment for keratoconus. The company sells through eye surgeons and clinics in the US and internationally, and reported record Q1 2026 net sales of roughly $150.6 million, up about 41% year over year, with its US glaucoma franchise up roughly 58% and iDose TR contributing around $54 million. The investment picture is a classic growth-versus-profitability tradeoff. Revenue is compounding quickly and management raised full-year 2026 net-sales guidance to roughly $620 million to $635 million, yet Glaukos is still reporting net losses (about $19.8 million, or $0.34 per share, in Q1 2026) as it spends heavily on commercial launches and R&D. It carries roughly $280 million in cash and short-term investments with no debt, which funds those launches, but the stock trades at a rich multiple of sales and a negative P/E, so the valuation leans on continued rapid adoption of iDose TR and Epioxa. Walnut is not an investment adviser; this is descriptive context, not a recommendation.
What's the case for buying GKOS?
1. iDose TR ramp
The iDose TR sustained-release glaucoma implant is the single biggest growth driver, contributing around $54 million in Q1 2026 and powering the US glaucoma franchise up roughly 58% year over year. Its adoption reflects a shift toward procedural, drug-eluting glaucoma care rather than daily eye drops. Continued reimbursement clarity and a growing base of peer-reviewed clinical evidence support the ramp.
2. Corneal health and Epioxa
The corneal-health segment (Photrexa and the newer Epioxa incision-free cross-linking therapy for keratoconus) is a second growth engine. A CMS permanent J-code for Epioxa helps de-risk near-term reimbursement and access as the launch scales. This diversifies Glaukos beyond glaucoma devices into rare corneal disease.
3. International expansion
International glaucoma procedures are growing, aided by the European commercial launch of iStent Infinite following EU MDR certification. Overseas markets broaden the addressable base beyond the US. This gives Glaukos additional runway even as domestic MIGS competition intensifies.
4. Path toward profitability
Rapid top-line growth combined with a debt-free balance sheet and roughly $280 million in cash gives Glaukos room to invest through its launches. Gross profit rose about 42% in Q1 2026, tracking sales. The open question is how quickly operating leverage turns the current net losses into sustained profit.
What are the risks to GKOS?
Glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Reimbursement complexity is a recurring watchpoint, including Medicaid Drug Rebate Program impacts that have muted Photrexa and general pricing pressure in glaucoma devices. Competition is intense from Alcon, Sight Sciences, AbbVie, Johnson & Johnson, and others across MIGS and glaucoma drug delivery, and a competitor supply recovery or new launch could erode share. The legacy iStent business has shown flattish trends outside iDose, and international markets face new competitive product trialing. Heavy spending relative to current earnings means execution and continued access to capital both matter.
How is GKOS valued? (as of MAY 2026)
Snapshot for GKOS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$470M
- Q1 2026 net sales: ~$150.6M (up ~41% YoY)
- 2026 revenue guidance: ~$620M to $635M
- Q1 2026 net loss: ~$19.8M (~$0.34/share)
- Market cap: ~$6B
- Cash and short-term investments: ~$280M (no debt)
Glaukos combines roughly 40% revenue growth with ongoing net losses, so it screens as a high-multiple growth medtech rather than a value name (negative trailing P/E). The debt-free balance sheet and roughly $280 million in cash fund the iDose TR and Epioxa launches. Wall Street price targets in 2026 ranged widely, from about $72 to $165, reflecting disagreement over how quickly the newer products scale.
How do you decide if GKOS is a buy?
Rather than asking whether GKOS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold GKOS indirectly through an index or sector ETF before adding more.
For the full picture, see the GKOS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about GKOS against your real portfolio and see your actual exposure before deciding.
The bottom line on GKOS
The bottom line: Glaukos Corporation's story right now is iDose TR ramp, with revenue (ttm) at ~$470M. If you believe that narrative continues, the call is about sizing GKOS sensibly and checking overlap with what you own; if you doubt it (the risk: glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around GKOS with Walnut
Use Glaukos Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is GKOS a good stock to buy right now?
+
The case for Glaukos Corporation right now is iDose TR ramp, with revenue (ttm) at ~$470M. If you believe that thesis holds, GKOS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Glaukos Corporation do?
+
Glaukos Corporation is a San Clemente, California ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease.
What are the main risks of GKOS?
+
Glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Reimbursement complexity is a recurring watchpoint, including Medicaid Drug Rebate Program impacts that have muted Photrexa and general pricing pressure in glaucoma devices. Competition is intense from Alcon, Sight Sciences, AbbVie, Johnson & Johnson, and others across MIGS and glaucoma drug delivery, and a competitor supply recovery or new launch could erode share. The legacy iStent business has shown flattish trends outside iDose, and international markets face new competitive product trialing. Heavy spending relative to current earnings means execution and continued access to capital both matter.
What does Glaukos (GKOS) do?
+
Glaukos is an ophthalmic medical technology and pharmaceutical company. It develops and sells treatments for glaucoma, corneal disorders, and retinal disease, including the iStent surgical implants, the iDose TR drug-delivery implant, and corneal therapies Photrexa and Epioxa.
Is Glaukos profitable?
+
Not yet on a net-income basis. Glaukos reported a net loss of roughly $19.8 million, or about $0.34 per share, in Q1 2026, as it invests heavily in commercial launches and R&D. Revenue and gross profit are growing quickly, but the company still runs net losses (as of May 2026).
How fast is Glaukos growing?
+
Very fast for a medtech company. Q1 2026 net sales rose about 41% year over year to roughly $150.6 million, and management raised full-year 2026 guidance to about $620 million to $635 million. The US glaucoma franchise grew roughly 58% year over year (as of May 2026).
What is iDose TR and why does it matter?
+
iDose TR is a sustained-release implant that delivers glaucoma medication inside the eye over an extended period, reducing reliance on daily eye drops. It is Glaukos's largest growth driver, contributing around $54 million in Q1 2026 and powering the US glaucoma segment.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell GKOS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.